These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25658382)

  • 1. Size dependent variations of phospholipid based vesicular drug carriers in systemic drug activity.
    Mukherjee B; Mondal L; Chakraborty S; Paul P; Choudhury A; Bhattacharya S; Hossain CM
    Curr Pharm Biotechnol; 2015; 16(4):380-91. PubMed ID: 25658382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal drug delivery systems: an update review.
    Samad A; Sultana Y; Aqil M
    Curr Drug Deliv; 2007 Oct; 4(4):297-305. PubMed ID: 17979650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.
    Kesharwani P; Kumari K; Gururani R; Jain S; Sharma S
    Curr Drug Metab; 2022; 23(9):678-692. PubMed ID: 35692131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-based delivery system for vaccine candidates: constructing an effective formulation.
    Giddam AK; Zaman M; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2012 Dec; 7(12):1877-93. PubMed ID: 23249332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes as biocompatible and smart delivery systems - the current state.
    Dymek M; Sikora E
    Adv Colloid Interface Sci; 2022 Nov; 309():102757. PubMed ID: 36152374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
    Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
    Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production.
    Moghimi SM; Hamad I; Andresen TL; Jørgensen K; Szebeni J
    FASEB J; 2006 Dec; 20(14):2591-3. PubMed ID: 17065229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.
    Gregoriadis G; Florence AT
    Drugs; 1993 Jan; 45(1):15-28. PubMed ID: 7680982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting microencapsulation of drugs in liposomes.
    Kulkarni SB; Betageri GV; Singh M
    J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcein release behavior from liposomal bilayer; influence of physicochemical/mechanical/structural properties of lipids.
    Maherani B; Arab-Tehrany E; Kheirolomoom A; Geny D; Linder M
    Biochimie; 2013 Nov; 95(11):2018-33. PubMed ID: 23871914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study.
    Zeng C; Jiang W; Tan M; Yang X; He C; Huang W; Xing J
    Eur J Pharm Sci; 2016 Mar; 85():123-31. PubMed ID: 26883760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate.
    Sheikholeslami B; Lam NW; Dua K; Haghi M
    Life Sci; 2022 Jul; 300():120574. PubMed ID: 35469915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
    Bhatia A; Kumar R; Katare OP
    J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends and developments in liposome drug delivery systems.
    Lian T; Ho RJ
    J Pharm Sci; 2001 Jun; 90(6):667-80. PubMed ID: 11357170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic action of phospholipase A₂ on liposomal drug delivery systems.
    Hansen AH; Mouritsen OG; Arouri A
    Int J Pharm; 2015 Aug; 491(1-2):49-57. PubMed ID: 26056930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Sojourn on Liposomal Delivery System: Recent Advances and Future Prospects.
    Kaur S; Singh D
    Assay Drug Dev Technol; 2023; 21(2):48-64. PubMed ID: 36856471
    [No Abstract]   [Full Text] [Related]  

  • 18. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
    Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
    J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal drug delivery, a novel approach: PLARosomes.
    Kozubek A; Gubernator J; Przeworska E; Stasiuk M
    Acta Biochim Pol; 2000; 47(3):639-49. PubMed ID: 11310966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in liposome surface modification for oral drug delivery.
    Nguyen TX; Huang L; Gauthier M; Yang G; Wang Q
    Nanomedicine (Lond); 2016 May; 11(9):1169-85. PubMed ID: 27074098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.